Objective: To determine if postponement of delivery to administer fetal lung maturation corticosteroids (PDACs) in mothers with antepartum eclampsia <34 weeks gestation benefits the fetus without compromising the mother.
Introduction
Antepartum eclampsia generally initiates a rapid series of interventions, including plans for timely delivery. Most cases of antepartum eclampsia occur preterm. 1 If gestational age (GA) is <34 weeks, the managing obstetrician is immediately confronted with a maternal-fetal conflict and contradiction in management recommendations based on what is best for both mother and fetus in this set of circumstances. On one hand, eclampsia is considered a severe life-threatening obstetric emergency or 'near-miss event' for the mother necessitating urgent medical intervention. 2 As stated by Leitch et al., 3 for eclampsia 'the mainstay of treatment has always been the delivery of the patient'. Thus, some consider eclampsia to be 'an absolute contraindication to expectant management'; [4] [5] [6] definitive treatment is recommended by some to be prompt termination of the pregnancy 'as soon as maternal hemodynamic stabilization is achieved'. 7, 8 Concerns about delay of delivery include fear of disease progression with multiorgan system deterioration, especially in the maternal central nervous system and sudden placental abruption that could threaten fetal wellbeing in utero and thereafter.
On the other hand, for fetal maturation benefit, the administration of corticosteroids to pregnant women at risk for preterm delivery before 34 weeks gestation has been a standard of practice for more than a decade since the 1994 National Institutes of Health (NIH) Consensus Conference released its recommendations. 9 Not only is neonatal mortality decreased with this therapy, but also a lower incidence and severity of respiratory distress syndrome and a reduced risk of severe intraventricular hemorrhage in preterm infants occurs. [10] [11] [12] [13] [14] Of particular concern in this setting is the finding that the risk of hyaline membrane disease in neonates <32 weeks of gestation is increased in patients with preeclampsia compared with others. 15 Thus, there are significant conflicting maternal-fetal interests that impact the decision-making process of the physician in this clinical situation. Added to this is the anxiety that providers feel when dealing with an undelivered patient with eclampsia, and the desire to accomplish delivery in order to initiate the road to recovery as soon as possible.
Following maternal stabilization and fetal status assessment of a recently eclamptic mother, having determined that immediate cesarean delivery is not mandated by compelling maternal or fetal reasons such as suspected abruptio placenta or placental insufficiency, the physician managing the patient <34 weeks gestation must address a number of decisions, including mode of delivery. Regardless of whether induction of labor to attempt vaginal delivery is selected or if obstetric factor(s) such as breech presentation or prior cesarean surgery is/are present to favor cesarean delivery in this clinical setting, short-term postponement of delivery to administer corticosteroid (PDAC) therapy for fetal benefit could be highly desirable if clinical circumstances permit this undertaking.
In this 9-year retrospective review of patients with antepartum eclampsia determined to be <34 weeks gestation at the time of eclamptic seizure, we investigate pregnancy outcomes for patients who did or did not receive corticosteroids for variable periods of time before delivery.
Methods
This is a case series report based on the retrospective review of all maternal-perinatal pairs with antepartum eclampsia between 24 and 34 weeks gestation that delivered in the University of Mississippi Medical Center/Winfred L Wiser Hospital for Women and Infants during the 9-year period between 1 January 1999 and 31 December 2007. The Institutional Review Board granted approval for this study. Inclusion criteria were eclampsia, GA X24, but <34 weeks, and delivery within the cited span of time. Eclampsia is defined as the occurrence of new-onset grand mal seizures in a woman with preeclampsia. 16 GA for study inclusion was established using a combination of obstetric (gestational dating and ultrasound examination) and newborn criteria. Patients were excluded from study consideration if antepartum eclampsia occurred outside the GA parameters, if eclampsia occurred postpartum or if the diagnosis of eclampsia could not be established apart from other neurological disorders (cerebral hemorrhage, central venous thrombosis, seizure disorder). Demographic variables, maternal outcomes and neonatal outcomes were collected.
Study subjects were subdivided into three groups according to length of corticosteroid course before delivery: group Ap24 h; group B >24 but <48 h; and group C X48 h. Available newborn medical records were reviewed to determine whether each newborn required immediate newborn intubation, continuous positive airway pressure, mechanical ventilation (MV), room air (RA) or was indeterminate.
Statistical analysis was performed with significance set at P<0.05. Data were analyzed by one-way analysis of variance, analysis of variance on ranks, w 2 -test and Fisher's exact test where appropriate.
Results
During the study period, 30 890 deliveries occurred and 68 patients merited a diagnosis of eclampsia. Excluding 31 patients with postpartum eclampsia or antepartum eclampsia occurring outside the desired GA parameters, the residual study group numbered 37 patients with the following group assignments: group A ¼ 28 patients, group B ¼ 5 patients and group C ¼ 4 patients. PDAC ranged from 0 to 215 h with a mean and median of 25 and 13 h, respectively. Among the patients in group A, corticosteroids were not administered before delivery in 7 cases and there were another 21 cases with PDAC that ranged from 0.9 to 22.5 h. The PDAC for the five patients in group B and four in group C ranged from 27 to 47 and 49 to 215 h, respectively. PDAC for two of four cases in group C was greater than the customary 48 h, as corticosteroids were administered before the onset of eclampsia for other obstetric indications (antepartum hemorrhage and pre-eclampsia). Delivery was promptly undertaken in these two cases with a PDAC >48 h following onset of eclampsia.
Maternal demographics, treatments, obstetric parameters and outcomes are tabulated in Tables 1 and 2 . The patients with hemolytic anemia, elevated liver enzymes and low platelets (HELLP) syndrome (n ¼ 5) were delivered in group A within the first 24 h after eclamptic convulsion. Vaginal delivery was accomplished successfully in 9 of 14 patients (64%), for whom it was attempted with cesarean delivery required for non-reassuring fetal status in 5 patients (36%). No observable adverse outcomes occurred as a result of trial of labor in any of the three patient groups.
During the interval between eclamptic seizure and delivery, while fetal lung maturation corticosteroids were administered, there were no cases of placental abruption, stillbirth, stroke, hypertensive emergency, recurrent seizure(s), congestive heart failure, renal deterioration or progression of HELLP Syndrome.
A single maternal death occurred in the series as a consequence of an erroneous administration of Pancuronium instead of Ativan in the adult emergency room of a community hospital before transfer to our institution. A witnessed seizure occurred just as an infusion of magnesium sulfate was being prepared for administration. Prior to that the mother at 25 to 26 weeks gestation was given Betamethasone and antihypertensives for severe hypertension; incomplete HELLP syndrome was diagnosed. The patient became apneic for 3 min following receipt of the Pancuronium until intubation was accomplished. Immediately following transfer to our regional center, the patient underwent emergent cesarean delivery, but could not be extubated following surgery. Mental status never improved postoperatively, suspected aspiration was treated but the patient became acutely hypotensive with respiratory distress on the third postoperative day and had a cardiac arrest. Resuscitation was unsuccessful.
The results of immediate and long-term neonatal outcomes for patients in each of the three groups are tabulated in Table 3 . Both MV and immediate newborn intubation occurred less often with increasing GA, and there was a reduction in their utility as the duration of PDAC increased. Immediate newborn intubation or continuous positive airway pressure was required for 23/28 in group A, 4/5 in group B and 2/4 in C; room air was sufficient at birth for 5/28 in group A, 1/5 in group B and 2/4 in C. No newborn >33 weeks gestation required immediate newborn intubation. Prolonged (that is, >1 day) MV was not required for any infant with a GA X32 weeks or PDAC X48 h. No neonatal deaths, necrotizing enterocolitis, intraventricular hemorrhage or postnatal infection occurred in any of the group B and C newborns, five of nine being male. The three neonatal deaths in group A were due to pulmonary prematurity in a 28-week male infant, pulmonary hypoplasia in a 24-week female infant and sepsis in a 29-week female infant with agenesis of the Corpus Callosum and lobar holoprosencephaly.
The effect of PDAC time interval and GA on duration of MV is illustrated in Figure 1 . PDAC for antepartum eclampsia appears to result in a more significant reduction in duration of MV in gestations <32 weeks than those X32 weeks.
Discussion
In this case series of 37 patients with antepartum eclampsia <34 weeks gestation, PDAC for pregnancies with antepartum eclampsia between 24 and 34 weeks gestation appears to offer notable fetal pulmonary benefit without significantly compromising maternal or fetal well-being. Inasmuch as prolonged MV (that is, >1 day) was not required in any infant with a GA X32 weeks or PDAC X48 h, PDAC for the mother with antepartum eclampsia may be a more compelling consideration when GA of 32 weeks has not yet been achieved. The small sample size, despite accrual over 9 years, does not allow for an adequate and true characterization of risks or benefits associated with PDAC in preterm eclampsia and precludes us from making definitive recommendations in support or against this practice.
We are not the first group of investigators to consider a more individualized approach to eclamptic patients <34 weeks gestation to administer, when possible, corticosteroids for fetal maturation. 17 Variables are quoted as a proportion or a median value with a range. a Not related to a delay in delivery to optimize fetal pulmonary function with steroid therapy. Where possible, resuscitation of the fetus in utero following an eclamptic seizure may be better for the fetus unless there is post-seizure persistent non-reassuring fetal status. 18 In the absence of further seizures with magnesium sulfate therapy, and as long as the mother remains stable, 'prolonging the pregnancy may be possible to improve the outcome of a premature fetus'. 19 Close fetal and maternal monitoring should be maintained throughout. 20 The patient must be made fully aware of the potential risks to herself in prolonging the pregnancy and in agreement with that plan of care.
Table 2 Maternal outcomes
In addition to neonatal pulmonary benefit associated with corticosteroids, 21 there might be several other potential maternal-fetal benefits associated with expectant management for corticosteroid therapy. Corticosteroids reduce the risk of severe intraventricular hemorrhage in preterm infants.
10-13,22 -24 One mechanism by which antenatal corticosteroid therapy impacts lung function positively is its demonstrated enhancement of endothelial nitric oxide synthase protein expression in the preterm lung at birth. 25 This may also relate to the demonstrated positive effect of corticosteroids with regard to increasing blood pressure in very preterm infants, thus decreasing the need for vasopressors and plasma expanders in very preterm infants during the first 24 h following birth. 26 The use of PDAC in an obstetric practice would also allow for the administration of other agents, such as magnesium sulfate in the preterm pregnancy complicated by eclampsia. The Magpie trial has shown that women with pre-eclampsia/eclampsia and their babies benefit from magnesium sulfate. 27 The maternal administration of this drug is associated with a subsequent reduction in the risk of fetal/neonatal intraventricular hemorrhage, cerebral palsy and pediatric mortality. 28 Intravenously infused magnesium sulfate in the mother with pre-eclampsia produces a sustained reduction in systemic vascular resistance and an increase in the cardiac index. 29 Inasmuch as posterior reversible leucoencephalopathy syndrome has been reported in some patients with eclampsia that undergo neuroimaging with magnetic resonance imaging, 30 the impact of PDAC intervention and magnesium sulfate on maternal formation and recovery from posterior reversible leucoencephalopathy syndrome deserves further study. Only five magnetic resonance imaging examinations were undertaken in the 37 patients studied, and this issue cannot be addressed well with the available data.
The absence of any evidence to suggest that PDAC caused maternal or fetal compromise in the current series is encouraging and significant. This finding lends further support for a prospective study of an approach to antepartum eclampsia <32 weeks that Figure 1 Postponement of delivery to administer corticosteroid (PDAC) (hours) and duration of mechanical ventilation (MV) (days) for infants <32 and X32 weeks gestation at birth; A1-B1-C1 are pregnancies <32 weeks and A2-B2-C2 are pregnancies X32 weeks.
Eclampsia <34 weeks and corticosteroids for fetal benefit KB Tam Tam et al considers postponement of delivery for 24 to 48 h to enable corticosteroids and magnesium sulfate therapy to potentially enhance the neonatal pulmonary and other maternal-fetal outcomes noted above. We suggest that such an undertaking should be structured to guarantee vigilant monitoring of both mother and child. This type of prospective randomized clinical trial design should also allow for analysis of data based on the actual intent to PDAC as opposed to immediate delivery at the onset of eclampsia. We envision that an immediate delivery option could allow for induction of labor or a cesarean and administration of corticosteroids until delivery is achieved. Patients in the PDAC arm should have the option of premature delivery if a compelling maternal or fetal reason to immediately end the pregnancy arises. An analysis of outcomes based on intent, rather than duration of PDAC realized, would be more meaningful for clinical practice and minimize the effects of confounding variables such as severity of the disease state on maternal-fetal outcomes. A similar analysis of data by the actual intent to PDAC was not possible in this study as corticosteroids were reflexively administered to many cases without first finalizing a delivery plan. In summary, the current state of the science on the management of patients with preterm (<34 weeks) eclampsia has not provided answers to all questions relating to the potential maternal-fetal benefits or risks from expectant management, corticosteroid and magnesium sulfate therapy. It is the opinion of the authors that management of these patients, pending such answers, should be tailored to each case based on maternal-fetal riskFbenefit analysis which should include, as borne out by this paper, a consideration of the GA and the degree of neonatal pulmonary benefit that can be realized from PDAC.
